Prognostic Comparison Between Triple Positive Breast Cancer And Her-2 Overexpression Breast Cancer

Breast cancer is one of the major diseases that threaten women’s health.The diagnosis and treatment of breast cancer has entered the molecular typing stage.Immunohistochemistry is closely related to the diagnosis,treatment and prognosis of breast cancer.Recently,the luminal B subtype in estrogen and progesterone receptor and HER-2 are positive for breast cancer has been concerned,is called triple positive breast cancer.In recent years,studies have shown that HR and Her-2 mediated signal transduction pathways in triple positive breast cancers intersect each other,reducing the effect of endocrine therapy and molecular targeted therapy,and further affecting the prognosis of triple positive breast cancer.This article reviewed the clinical data of 141 cases of triple positive breast cancer and 140 cases of Her-2 overexpression breast cancer,compared the prognosis of both and analyzed the effects of estrogen and progesterone receptors on molecular targeted therapy,thereby revealing the resistance of triple positive breast cancer.Objective:To compare the prognosis of triple positive and Her-2 overexpression breast cancer and analyze the effect of estrogen and progesterone receptor expression on the prognosis of triple-positive breast cancer.As to evaluate the effectiveness of molecular targeted therapy for triple-positive breast cancer.Methods:This study is a retrospective review of 141 cases of triple positive breast cancer and 140 cases of Her-2 overexpression breast cancer clinical data.The prognosis of triple positive and Her-2 overexpression breast cancer was compared.The effects of different estrogen and progesterone receptors on the molecular targeted therapy of triple-positive breast cancer were analyzed.SPSS 24.0 statistical software were employed to analyze the statistical clinicopathological information and prognosis.Kaplan-Meier method has been used to analyze the Survival analysis.Log-rank test has been used to analyze survival curves.The statistical results with P<0.05 were statistically significant.Results:By statistical comparison of clinicopathological data of triple-positive and Her-2 overexpression breast cancer,there were no significant differences in the prognostic factors of age,tumor size,lymph node status,pathological stage,histological grade and Ki-67 between the two groups.The OS of triple-positive breast cancer was better than that of Her-2 overexpression breast cancer(P= 0.025),but there was no significant difference of the DFS between the two groups.Subgroup analysis showed that with or without molecular targeted therapy,triple positive breast cancer prognosis is superior to Her-2 overexpression breast cancer,but there was no significant difference of DFS and OS.According to the different expression levels of ER and PR,we compared the effects of molecular targeted therapy on the prognosis of patients with triple-positive breast cancer.When PR <50% and HR <50%,the DFS of the triple-positive breast cancer used molecular targeted therapy group was significantly better than that of the unused group(P= 0.038,P= 0.045).While PR350% and HR350%,molecular targeted therapy did not significantly improve DFS in triple-positive breast cancer patients(P= 0.7,P= 0.616).Conclusion:The prognosis of triple positive breast cancer is better than that of Her-2 overexpression breast cancer,and the benefit of trastuzumab in triple positive breast cancer with high expression of estrogen and progesterone receptors is small.